REMS Online Supplement

This educational supplement has been created to educate healthcare professionals on the safe and proper use of Extended Release (ER) and Long Acting (LA) opioids for chronic pain management. Opioids are the cornerstone of modern pain management. They are highly complex molecules which require knowledge and integration of basic science,clinical, pharmacological, psychosocial, abuse, diversion, and public health aspects of opioids. This Opioid Risk Evaluation and Mitigation Strategy (REMS) supplement is a valuable tool that can be utilized daily by everyone in your practice. Continuing Medical Education (CME/CE) credits are available for studying this supplement and completing the online test. The supplement and test can be completed in a little more than three hours, but it will have a lifetime benefit!

Target Audience

The target audience includes all clinicians registered with the DEA, eligible to prescribe schedule 2 or 3 drugs that have written at least one ER/LA opioid prescription in the past year, including primary care (family practice and internal medicine); anesthesiology (including pain management); oncology; neurology; orthopedics; PM&R and palliative care physicians, physician assistants and nurse practitioners. Pharmacists would also benefit from this education.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Utilize available screening tools for the effective assessment of patients before initiating opioid therapy (Blueprint sections I and II)
  2. Implement opioid risk-reduction strategies based on a patient’s aberrant behavior (Blueprint sections I and II)

  3. Apply communication strategies to strengthen relationships with patients and improve patient knowledge of their opioid treatment (Blueprint sections III and IV)

  4. Properly monitor patients on opioid therapy utilizing available resources, including Patient-Provider Agreements and state Prescription Drug Monitoring Programs (Blueprint sections III and IV)

  5. Identify potential adverse events in patients on opioid therapy (Blueprint sections V and VI)

  6. Mitigate drug-drug interactions with patients on opioid therapy(Blueprint sections V and VI)

Faculty

Paul A. Sloan, MD
Department of Anesthesiology
University of Kentucky Medical Center
Lexington, Kentucky

 Mellar P. Davis, MD, FCCP
Department of Solid Tumor Oncology
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio
 

Pamel Gamier, RN, BSN, CHPN
Department of Solid Tumor Oncology
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio

Disclosure Statements

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) and Dannemiller that any person who is in a position to control the content of a CME/CE activity must disclose all relevant financial relationships they have with a commercial interest. The faculty and non-faculty reported the following regarding financial relationships that they or their spouse/life partners have or do not have with commercial interests:

Name of Faculty or PresenterRelationship Identified With:

Paul A. Sloan, MD

Consultant/Advisor: Mallinckrodt Pharmaceuticals.
Mellar P. Davis, MD, FCCPResearch Grant: Pfizer, Inc.
Pamela Gamier, RN, BSN, CHPNHas disclosed no relevant financial relationships.

Non-faculty: Perry Fine, MD, content reviewer disclosed that he is a consultant/advisor for kaléo, Inc.; Pfizer, Inc.; Zogenix, Inc., and Magellan Health, Inc. All others, including their spouse/life partners, have no financial relationships to report: Bernard Abrams, MD, Dannemiller Medical Director, content reviewer; Sandy Breslow; Richard DeVito, Jr.; Brynne Hunter and Michelle Montgomery; Elsevier, Dannemiller and Journal of Opioid Management staff.

Finacial Support

This activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and Dannemiller.

Course Open Date: March 19, 2015 | Course Expiration Date: September 19, 2016

CME Credit (Physicians)

This activity has been planned and implemented with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through co-providership of the Elsevier Office of Continuing Medical Education and Dammiiller. The Elsevier Office of CME is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP Credit (Nurse Practitioners)

Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education . Provider Number 090419. This program was is accredited for 3.0 contact hours.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, Dannemiller, Inc. and ER/LA Opioid Analgesic REMS Program Companies do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation:

  • In order to claim credit, participants must complete the following:
  • Read the learning objectives, accreditation information and disclosures at the beginning of this activity.
  • Complete the pre-activity test.http://vts.inxpo.com/Launch/Event.htm?ShowKey=23754
  • Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation. Once you successfully complete the post-test (score of 70% or higher) and activity evaluation, your Statement of Credit will be made available immediately.
  • Click on View Certificate and print the Statement of Credit for your records.
Course summary
Course opens: 
03/19/2015
Course expires: 
09/19/2016
Rating: 
0

Available Credit

Accreditation Period

Course opens: 
03/19/2015
Course expires: 
09/19/2016
Please login or register to take this course.